Synendos Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Synendos aims to develop breakthrough safe and effective therapies for neuropsychiatric disorders through the modulation of a new drug target that enables restoration of natural functioning of the brain. Synendos' current focus is on anxiety and mood-related diseases with high unmet medical need as post-traumatic stress disorder. Synendos advances the preclinical and clinical development of selective endocannabinoid reuptake inhibitors (first-in-class), which are covered by strong IP. An IND enabled, FIH, phase I trial is anticipated by 2022 and will be followed by Phase II. Synendos is developing a parallel de-risking strategy aimed at obtaining fast and cost-effective clinical PoC (Phase Ib) in a relevant CNS disease (small size, defined regulatory route, high unmet need and easy-to-assess endpoint). The financial strategy envisages CHF 20m to reach first clinical PoC. We identified two lead investors (term sheet available) and seek additional investors to complete the syndicate
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
First-in-class inhibitors (small molecules)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO, co-founder
Synendos Therapeutics